Galapagos NV operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galapagos NV with three other
miscellaneous service companies in Europe:
Genmab A/S
of DENMARK
(2019
sales of 5.37 billion Danish Kroner [US$854.32 million]
of which 100%
was Royalties),
Clinigen Group PLC
of UNITED KINGDOM
(£456.90 million [US$598.82 million]
of which 45%
was Unlicensed Medicines), and
Genus plc
which is
also
based in UNITED KINGDOM
(£488.50 million [US$640.24 million]
of which 52%
was Operating Genus PIC).
Sales Analysis.
Sales increased substantially in 2019:
Galapagos NV reported sales of 895.89 million Euro (US$1.06 billion)
for the
year ending
December of 2019.
This
represents
an
increase of 181.9%
versus 2018, when the company's sales were 317.85 million Euro.
This was the fourth straight year of sales growth at Galapagos NV.
Sales of R&d saw an increase
of
199.6% in 2019, from
278.67 million Euro to 834.90 million Euro.
Not all segments of Galapagos NV experienced an increase in sales in 2019:
sales of Fee-For-Services fell 0.8% to 10.08 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).